A Study of Thioctic Acid and Deprenyl in HIV-Infected Patients With Dementia

This study has been completed.
Information provided by:
NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:
First received: November 2, 1999
Last updated: June 23, 2005
Last verified: March 1996
The purpose of this study is to see if it is safe and effective to give thioctic acid and deprenyl (selegiline hydrochloride), alone or in combination, to HIV-infected patients who have mild to moderate dementia (a decline in their mental abilities).

Condition Intervention Phase
Cognitive Disorders
HIV Infections
Drug: Thioctic acid
Drug: Selegiline hydrochloride
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Parallel Group, Placebo-Controlled, Tolerability and Safety Study of Thioctic Acid and Deprenyl in HIV Dementia

Resource links provided by NLM:

Further study details as provided by NIH AIDS Clinical Trials Information Service:

Estimated Enrollment: 32
Detailed Description:
Patients are randomized to receive thioctic acid alone, deprenyl alone, thioctic acid/deprenyl, or placebo alone for 10 weeks, after which all patients may receive active drug on an open-label basis. Patients must have seven clinic visits.

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria

Concurrent Medication:


  • Antiretrovirals provided dose has been stable for at least 6 weeks prior to study entry.

Patients must have:

  • HIV seropositivity.
  • Mild to moderate cognitive impairment (problems with short term memory, concentration, and feeling slowed down).
  • No active opportunistic CNS infection.
  • Ability to give informed consent.

Prior Medication:


  • Prior antiretrovirals provided dose has been stable for at least the past 6 weeks.
  • Prior thioctic acid or deprenyl.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

  • Severe premorbid psychiatric illness including schizophrenia and major depression that would interfere with study compliance.
  • CNS neoplasms.
  • Any other clinically significant condition or laboratory abnormality that would preclude participation on study.
  • Current participation in other drug studies.

Concurrent Medication:


  • Chemotherapy for malignancy.

Patients with the following prior conditions are excluded:

  • History of chronic neurological disorders such as serious head injury, documented stroke, multiple sclerosis, uncontrolled epilepsy, Tourette's syndrome, and other neurodegenerative processes such as Huntington's disease.
  • Prior participation in this study.
  • History of adverse reaction/allergy to thioctic acid or deprenyl.

Prior Medication:


  • Other investigational drugs within 30 days prior to study entry.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00002154

United States, Maryland
Johns Hopkins Hosp
Baltimore, Maryland, United States, 212876965
United States, New York
Columbia Univ
New York, New York, United States, 10032
Univ of Rochester Med Ctr
Rochester, New York, United States, 14642
Sponsors and Collaborators
The Dana Foundation
  More Information

ClinicalTrials.gov Identifier: NCT00002154     History of Changes
Other Study ID Numbers: 250A  03-D95 
Study First Received: November 2, 1999
Last Updated: June 23, 2005
Health Authority: United States: Food and Drug Administration

Keywords provided by NIH AIDS Clinical Trials Information Service:
Drug Therapy, Combination
Cognition Disorders
Acquired Immunodeficiency Syndrome
AIDS-Related Complex
Thioctic Acid

Additional relevant MeSH terms:
Cognition Disorders
Mental Disorders
Neurocognitive Disorders
Thioctic Acid
Growth Substances
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Protective Agents
Vitamin B Complex

ClinicalTrials.gov processed this record on May 23, 2016